Answers are grounded in this paper and cite their sources.
Introduction: Pegilated interferon alpha-2a 40KD (Pegasys?) is registered in European Union, and is indicated for the treatment of HBeAg positive or HBeAg negative chronic hepatitis B in adult patients with compensated liver disease, evidence of viral replication and increased ALT. The aim of this study was to evaluate efficacy and safety of Pegasys? for Pegasys?
No takes yet. Share an insight, caveat, or question.
Vīksna et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: